Population Sciences, Translational Research, and the Opportunities and Challenges for Genomics to Reduce the Burden of Cancer in the 21st Century

Overview

Journal Cancer Epidemiol Biomarkers Prev

Specialties Biochemistry
Oncology
Public Health

Date 2011 Jul 29

PMID 21795499

Citations 27

Authors

Muin J Khoury

Steven B Clauser

Andrew N Freedman

Elizabeth M Gillanders

Russ E Glasgow

William M P Klein

Sheri D Schully

Affiliations

Soon will be listed here.

Abstract

Advances in genomics and related fields are promising tools for risk assessment, early detection, and targeted therapies across the entire cancer care continuum. In this commentary, we submit that this promise cannot be fulfilled without an enhanced translational genomics research agenda firmly rooted in the population sciences. Population sciences include multiple disciplines that are needed throughout the translational research continuum. For example, epidemiologic studies are needed not only to accelerate genomic discoveries and new biological insights into cancer etiology and pathogenesis, but to characterize and critically evaluate these discoveries in well-defined populations for their potential for cancer prediction, prevention and response to treatment. Behavioral, social, and communication sciences are needed to explore genomic-modulated responses to old and new behavioral interventions, adherence to therapies, decision making across the continuum, and effective use in health care. Implementation science, health services, outcomes research, comparative effectiveness research, and regulatory science are needed for moving validated genomic applications into practice and for measuring their effectiveness, cost-effectiveness, and unintended consequences. Knowledge synthesis, evidence reviews, and economic modeling of the effects of promising genomic applications will facilitate policy decisions and evidence-based recommendations. Several independent and multidisciplinary panels have recently made specific recommendations for enhanced research and policy infrastructure to inform clinical and population research for moving genomic innovations into the cancer care continuum. An enhanced translational genomics and population sciences agenda is urgently needed to fulfill the promise of genomics in reducing the burden of cancer.

Citing Articles

Factors Associated with the Uptake of Genetic Testing for Cancer Risks: A Pathway Analysis Using the Health Information National Trends Survey Data.

Dong X, Huang J, Yi Y, Zhang L, Li T, Chen Y Life (Basel). 2022; 12(12).

PMID: 36556389 PMC: 9786267. DOI: 10.3390/life12122024.

A systematic review of theory-informed strategies used in interventions fostering family genetic risk communication.

Zhao J, Guan Y, McBride C Patient Educ Couns. 2022; 105(7):1953-1962.

PMID: 35304074 PMC: 9203975. DOI: 10.1016/j.pec.2022.03.009.

Home testing for COVID-19 and other virus outbreaks: The complex system of translating to communities.

Lyon V, LeRouge C, Fruhling A, Thompson M Health Syst (Basingstoke). 2021; 10(4):298-317.

PMID: 34745591 PMC: 8567871. DOI: 10.1080/20476965.2021.1952905.

A scoping review of social and behavioral science research to translate genomic discoveries into population health impact.

Allen C, Peterson S, Khoury M, Brody L, McBride C Transl Behav Med. 2020; 11(4):901-911.

PMID: 32902617 PMC: 8240657. DOI: 10.1093/tbm/ibaa076.

Navigating the Intersection between Genomic Research and Clinical Practice.

Daly M Cancer Prev Res (Phila). 2020; 13(3):219-222.

PMID: 32132115 PMC: 7080295. DOI: 10.1158/1940-6207.CAPR-19-0267.

References

Kawamoto K, Lobach D, Willard H, Ginsburg G . A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine. BMC Med Inform Decis Mak. 2009; 9:17. PMC: 2666673. DOI: 10.1186/1472-6947-9-17. View

Hamburg M, Collins F . The path to personalized medicine. N Engl J Med. 2010; 363(4):301-4. DOI: 10.1056/NEJMp1006304. View

Condit C, Shen L . Public understanding of risks from gene-environment interaction in common diseases: implications for public communications. Public Health Genomics. 2010; 14(2):115-24. PMC: 3214934. DOI: 10.1159/000314915. View

Rabin B, Glasgow R, Kerner J, Klump M, Brownson R . Dissemination and implementation research on community-based cancer prevention: a systematic review. Am J Prev Med. 2010; 38(4):443-56. DOI: 10.1016/j.amepre.2009.12.035. View

Swanton C, Caldas C . From genomic landscapes to personalized cancer management-is there a roadmap?. Ann N Y Acad Sci. 2010; 1210:34-44. DOI: 10.1111/j.1749-6632.2010.05776.x. View

Wilffert B, Swen J, Mulder H, Touw D, der Zee A, Deneer V . From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Int J Clin Pharm. 2011; 33(1):3-9. DOI: 10.1007/s11096-011-9485-2. View

Stokols D, Hall K, Taylor B, Moser R . The science of team science: overview of the field and introduction to the supplement. Am J Prev Med. 2008; 35(2 Suppl):S77-89. DOI: 10.1016/j.amepre.2008.05.002. View

Antoniou A, Wang X, Fredericksen Z, McGuffog L, Tarrell R, Sinilnikova O . A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet. 2010; 42(10):885-92. PMC: 3130795. DOI: 10.1038/ng.669. View

. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?. Genet Med. 2009; 11(1):66-73. PMC: 2743614. DOI: 10.1097/GIM.0b013e3181928f56. View

10.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

11.

Landi M, Chatterjee N, Yu K, Goldin L, Goldstein A, Rotunno M . A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet. 2009; 85(5):679-91. PMC: 2775843. DOI: 10.1016/j.ajhg.2009.09.012. View

12.

Roth J, Garrison Jr L, Burke W, Ramsey S, Carlson R, Veenstra D . Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics. 2010; 14(2):59-67. PMC: 3214932. DOI: 10.1159/000290452. View

13.

Lander E . Initial impact of the sequencing of the human genome. Nature. 2011; 470(7333):187-97. DOI: 10.1038/nature09792. View

14.

Moasser M . Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene. 2007; 26(46):6577-92. PMC: 3071580. DOI: 10.1038/sj.onc.1210478. View

15.

Schully S, Benedicto C, Gillanders E, Wang S, Khoury M . Translational research in cancer genetics: the road less traveled. Public Health Genomics. 2010; 14(1):1-8. PMC: 3025883. DOI: 10.1159/000272897. View

16.

Freedman A, Sansbury L, Figg W, Potosky A, Weiss Smith S, Khoury M . Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010; 102(22):1698-705. PMC: 2982809. DOI: 10.1093/jnci/djq390. View

17.

Maris J, Mosse Y, Bradfield J, Hou C, Monni S, Scott R . Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008; 358(24):2585-93. PMC: 2742373. DOI: 10.1056/NEJMoa0708698. View

18.

Ladanyi M, Hogendoorn P . Cancer biology and genomics: translating discoveries, transforming pathology. J Pathol. 2010; 223(2):99-101. DOI: 10.1002/path.2812. View

19.

Pawson R, Greenhalgh T, Harvey G, Walshe K . Realist review--a new method of systematic review designed for complex policy interventions. J Health Serv Res Policy. 2005; 10 Suppl 1:21-34. DOI: 10.1258/1355819054308530. View

20.

Petersen G, Amundadottir L, Fuchs C, Kraft P, Stolzenberg-Solomon R, Jacobs K . A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 2010; 42(3):224-8. PMC: 2853179. DOI: 10.1038/ng.522. View